OXFORD, UK, Sept. 13, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (Nasdaq: VACC) is a clinical-stage biopharmaceutical company discovering and developing novel T-cell immunotherapies aimed at In Harnessing the Power of the Immune System to Treat Chronic Infectious Diseases, Cancer and Autoimmunity, today announced a key opinion leader (KOL) webinar to discuss the current treatment landscape and functional cures for people with chronic hepatitis B virus (HBV) infection potential ways. Details are as follows:
KOL Webinar: In Search of a Functional Cure for Chronic Hepatitis B
Wednesday, September 20, 2023, 14:00-15:00 Eastern Time.
To register for the event, click here.
The event will feature the following renowned thought leaders who will discuss the current treatment landscape for patients with hepatitis B, combination approaches to improve functional cure rates, and the potential of antigen-specific immunotherapeutics:
-
Eleanor Barnes, MBBS, PhD, FRCP, FMedSciProfessor of Hepatology and Experimental Medicine and Ludwig Adjunct Scholar; Nuffield Department of Medicine, University of Oxford, co-inventor of VTP-300.
-
Ed Gane, MBChB, MD, FRACP, MNZMprofessor of medicine at the University of Auckland, New Zealand; chief hepatologist, transplant physician and deputy director of the New Zealand Liver Transplantation Department, Auckland City Hospital.
The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy shown to induce sustained reductions in hepatitis B surface antigen, a marker of the disease. Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of a search for treatment options that may lead to a functional cure for HBV.
Vaccitech is currently conducting two trials targeting HBV. A Phase 2b clinical trial (HBV003; NCT05343481) is evaluating low-dose nivolumab, additional doses of the VTP-300 MVA component, and the timing of nucleos